Search results
Results from the WOW.Com Content Network
This is a list of investigational social anxiety disorder drugs, or drugs that are currently under development for clinical use in the treatment of social anxiety disorder (SAD; or social phobia) but are not yet approved. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses.
This is a list of investigational anxiolytics, or anxiolytics that are currently under development for clinical use but are not yet approved. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses. This list was last comprehensively updated in June 2017.
This is a list of psychiatric medications used by psychiatrists and other physicians to treat mental illness or distress. The list is ordered alphabetically according to the condition or conditions, then by the generic name of each medication. The list is not exhaustive and not all drugs are used regularly in all countries.
Stelazine (trifluoperazine) – an antipsychotic used in the treatment of psychotic disorders, anxiety, and nausea caused by chemotherapy [2] Strattera (atomoxetine) – a non-stimulant medication used to treat ADHD; Suboxone (buprenorphine/naloxone) - a partial opioid agonist used in the treatment of opioid use disorder
This is an alphabetical list of psychiatric medications used by psychiatrists and other physicians to treat mental illness or distress. The list is not exhaustive. All mentioned drugs here are generic names. Not all drugs listed are used regularly in all countries.
These are lists of investigational drugs: List of investigational analgesics; List of investigational antidepressants; List of investigational antipsychotics; List of investigational anxiolytics; List of investigational attention deficit hyperactivity disorder drugs; List of investigational autism and pervasive developmental disorder drugs
Adagrasib, sold under the brand name Krazati, is an anticancer medication used to treat non-small cell lung cancer. [1] [2] Adagrasib is an inhibitor of G12C mutated KRAS GTPase. [1] It is taken by mouth. [1] It is being developed by Mirati Therapeutics. [1] [5]
K-Ras(G12C) inhibitor 6 is an irreversible inhibitor of oncogenic K-Ras(G12C), subverting the native nucleotide preference to favour GDP over GTP. Its family of inhibitors allosterically control GTP affinity and effector interactions by fitting inside a "pocket", or binding site, of mutant K-Ras .